02/26/2021 17:53
Clarín.com
Society
Updated 02/26/2021 18:20
The Ministry of Health of the Nation reported this Friday
another 92 deaths and 5,083 new positive cases
of coronavirus throughout the national territory.
Thus, Argentina reached 51,887 fatalities and 2,098,728 infections since the detection of the first infected in the country, a fact that turns one year old next Wednesday.
Of the last registered deaths (49 women, 46 men and three of whom the sex was not specified), 30 resided in the province of Buenos Aires, 24 in the City of Buenos Aires (CABA), 10 in Santa Fe, five in Black river;
four in Corrientes and Córdoba;
three from Tierra del Fuego;
two from Entre Ríos, Neuquén and Santiago del Estero;
and one from Chaco, Mendoza, Misiones and San Juan.
With cases in all jurisdictions, the province of Buenos Aires accumulated the highest number, with 2,088 positives, followed by the City of Buenos Aires (607), Córdoba (416), Santa Fe (261) and Corrientes (223).
Then came Neuquén (173), Río Negro (146), Mendoza (137), Tucumán (127), Misiones (116) and Chaco (103).
They completed the part Entre Ríos (92), Catamarca (83), Jujuy (83), Chubut (71), Salta (68), Santiago del Estero (67), Santa Cruz (60), La Pampa (53), San Juan (35), Tierra del Fuego (27), Formosa (23), La Rioja (21) and San Luis (3).
Of the 154,007 people who are suffering from the disease, 3,475 remain hospitalized in Intensive Care Units (ICU), whose bed occupancy level is 60.2% in the Metropolitan Area of Buenos Aires (AMBA) and 54.1% in the rest of the country.
In the last hours, 43,445 tests were carried out, with a positivity of 11.6%.
Since the beginning of the outbreak, 7,365,796 diagnostic tests have been performed for this disease.
This is equivalent to 161,600 samples per million inhabitants.
Meanwhile, the
Richmond laboratory
in Argentina signed a memorandum of understanding with the Russian Direct Investment Fund (RDIF) to produce the Sputnik V vaccine in the country, a development in which the Indian Hetero laboratory, in charge of transferring the technology, will participate.
"We are aiming to have vaccination plants because we think that unfortunately this type of pandemic is here to stay," said the director of Technical and Scientific Affairs of the Richmond laboratory, Elvira Zini, about the agreement and remarked that the decision "guarantees us a future of provision "of doses for immunization.
The agreement was signed in Moscow by
Tagir Sitdekov,
representing RDIF, and Marcelo Figueiras, president of Richmond, according to a note released by the local company.
After hearing the announcement, Figueiras explained that the manufacture of Sputnik V "will be carried out with the participation of Hetero Labs Limited, a laboratory established in India, with whom Richmond has had a strategic alliance for more than 25 years."
Production of the Sputnik vaccine in the country would take at least a year.
He also celebrated that this alliance favored the signing of the memorandum since the Gamaleya Institute, developer of Sputnik V, "is focused on the scale of production and cannot be dealing with the transfer of technology", which will be in charge of Hetero.
"
It is a process of a year, at least
, with which it is not to create expectations now but tomorrow not to fall back on waiting for vaccines to arrive from outside and have a local production," said the president of Richmond in statements to radio Miter.
The laboratory, which has a plant in the Buenos Aires municipality of Pilar, will build another to manufacture Sputnik, which will take at least a year.
Regarding the financing of the entire project, Figueiras said that it is
"a mix of own capital and local partners
who are willing to bet," he specified that "it is very expensive, between 60 and 90 million dollars" and pointed out that "no there is state money "at stake.
Regarding the agreement, the Minister of Science, Technology and Innovation, Roberto Salvarezza, said in an interview with Public Television that "it is an agreement between the private parties", and that the role of the Argentine State was "to bring the parties closer together." .
"One can assume that Argentina will have priority, in the same way as AstraZéneca's production in the mAbxience laboratory has a part reserved for the country," exemplified the head of the scientific portfolio.
Asked if it is possible for other laboratories to produce in Argentina, Salvarezza pointed out that "the possibilities exist. Argentine laboratories have the capacity to produce. Since mAbxience has produced 12 million doses, it shows that national laboratories have the capacity to make. No another deal would be surprising. "
